313 related articles for article (PubMed ID: 25411964)
1. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.
Khongkow P; Gomes AR; Gong C; Man EP; Tsang JW; Zhao F; Monteiro LJ; Coombes RC; Medema RH; Khoo US; Lam EW
Oncogene; 2016 Feb; 35(8):990-1002. PubMed ID: 25961928
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer.
Wen N; Wang Y; Wen L; Zhao SH; Ai ZH; Wang Y; Wu B; Lu HX; Yang H; Liu WC; Li Y
J Transl Med; 2014 May; 12():134. PubMed ID: 24885308
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 Promotes Drug Resistance in Cervical Cancer Cells by Regulating ABCC5 Gene Transcription.
Hou Y; Dong Z; Zhong W; Yin L; Li X; Kuerban G; Huang H
Biomed Res Int; 2022; 2022():3032590. PubMed ID: 35141332
[TBL] [Abstract][Full Text] [Related]
9. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.
Lok GT; Chan DW; Liu VW; Hui WW; Leung TH; Yao KM; Ngan HY
PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223
[TBL] [Abstract][Full Text] [Related]
10. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel.
Li X; Qiu W; Liu B; Yao R; Liu S; Yao Y; Liang J
J Transl Med; 2013 Sep; 11():204. PubMed ID: 24004449
[TBL] [Abstract][Full Text] [Related]
11. FoxM1 mediates resistance to herceptin and paclitaxel.
Carr JR; Park HJ; Wang Z; Kiefer MM; Raychaudhuri P
Cancer Res; 2010 Jun; 70(12):5054-63. PubMed ID: 20530690
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK.
Tang Q; Xu A; Yang Y; Zhang Y; Sun J
Discov Med; 2023 Jun; 35(176):208-220. PubMed ID: 37272088
[TBL] [Abstract][Full Text] [Related]
13. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
14. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer.
Zhou J; Wang Y; Wang Y; Yin X; He Y; Chen L; Wang W; Liu T; Di W
PLoS One; 2014; 9(5):e96989. PubMed ID: 24824601
[TBL] [Abstract][Full Text] [Related]
16. Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents.
Nakagawa-Saito Y; Mitobe Y; Suzuki S; Togashi K; Sugai A; Kitanaka C; Okada M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445993
[TBL] [Abstract][Full Text] [Related]
17. High FOXM1 expression was associated with bladder carcinogenesis.
Liu D; Zhang Z; Kong CZ
Tumour Biol; 2013 Apr; 34(2):1131-8. PubMed ID: 23325617
[TBL] [Abstract][Full Text] [Related]
18. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
[TBL] [Abstract][Full Text] [Related]
19. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
20. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
